This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / Avalyn Pharma presents AP01 data
Tech clinical trial data

Avalyn Pharma presents AP01 data

Analysis based on 6 articles · First reported May 21, 2026 · Last updated May 21, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The positive long-term data for AP01 from Avalyn Pharma could lead to increased investor confidence and a potential rise in the company's stock price. This development may also signal a shift in the treatment paradigm for pulmonary fibrosis, impacting the broader biotechnology and pharmaceutical sectors.

Biotechnology Pharmaceuticals
Event Summary

Avalyn Pharma Inc. announced an upcoming poster presentation at the European Alliance of Associations for Rheumatology (EULAR) 2026 conference in United Kingdom — London, England. The presentation will highlight updated findings from the ATLAS open-label extension trial, showcasing the long-term tolerability profile of AP01 (inhaled pirfenidone) in patients with progressive pulmonary fibrosis, with data extending up to four years of treatment. Prof. Anna-Maria Hoffmann-Vold from Oslo University Hospital and University Hospital of Zurich will be presenting these findings. This event underscores Avalyn Pharma's commitment to developing inhaled therapies for serious respiratory diseases and could significantly impact the future treatment landscape for pulmonary fibrosis.

Entities Involved
priv
Avalyn Pharma
Avalyn Pharma is presenting positive long-term data for its AP01 inhaled pirfenidone, which could enhance its market position in treating pulmonary fibrosis and other respiratory diseases. This event highlights the company's progress in developing optimized inhaled therapies.
Importance 100.0 Sentiment 70.0
per
Anna-Maria Hoffmann-Vold
Anna-Maria Hoffmann-Vold is a speaker at the EULAR 2026 conference, presenting the data on AP01 for progressive pulmonary fibrosis.
Importance 40.0 Sentiment 0.0
ngo
European Alliance of Associations for Rheumatology
The European Alliance of Associations for Rheumatology is hosting the EULAR 2026 conference where Avalyn Pharma will present its clinical trial data.
Importance 30.0 Sentiment 0.0
loc
United Kingdom — London
United Kingdom — London is the location where the European Alliance of Associations for Rheumatology 2026 conference is being held.
Importance 5.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.